Kevzara fails in PhIII COVID-19 trial
Sanofi and Regeneron do not anticipate carrying out further research on Kevzara in COVID-19
Read More
Tag: Kevzara
Sanofi, Regeneron pull plug on Kevzara COVID-19 trial
The drug failed to show any significant benefit in patient requiring mechanical ventilation
Read More
SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Final NICE nod for Sanofi’s Kevzara
The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).
Read More
Sanofi’s Kevzara will be funded for NHS use
Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.
Read More
Sanofi, Regeneron’s biologic gets EU nod for rheumatoid arthritis
Sanofi and Regeneron’s Kevzara has been approved by European regulators to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
Green light for Sanofi, Regeneron’s Kevzara
Sanofi and Regeneron’s Kevzara has been cleared in the US to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
